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Abstract
Background/Aims: There is a growing body of evidence that the long-term hemodialysis 
(HD) treatment leads to disturbances of carnitine homeostasis but the results of L-carnitine 
supplementation in HD patients have been conflicting. In the present prospective study, we 
investigated the effectiveness of intravenous L-carnitine in mitigating dialysis-related protein-
energy wasting (PEW) based on pre-treatment albumin levels. Methods: Fifty patients (46% 
male, mean age 63±18.28 years, HD vintage 37.5 (7-288) months) received 1 g L-carnitine 
intravenously at the end of every HD session for 12 months. Clinical data were obtained from the 
medical records and charts. Intradialytic hypotension periods (defined as a decrease of systolic 
blood pressure by ≥ 20 mmHg) were recorded. Dietary habits were evaluated using a self-
administered questionnaire prior to L-carnitine supplementation. Laboratory parameters were 
measured prior to the supplementation and controlled in 6-months intervals. Anthropometric 
measurements were performed prior to HD session, including „dry“ body weight and height, 
body mass index (BMI), and body composition analysis using bioimpedance spectroscopy. 
Malnutrition-inflammation score (MIS) was used as a scoring system representing the severity 
of PEW and an indicator of general functional capacity. Results: A significant increase in total 
cholesterol, predominantly on the account of LDL was found (p=0.005). Simultaneously, HDL 
decreased (p=0.001) while triglyceride levels remained unchanged. Although the rise in serum 
prealbumin could be observed, lean tissue index (LTI) decreased and fat tissue index (FTI) 
increased which resulted in reduction of the LTI/FTI ratio (p=0.002). When divided into two 
groups according to the pre-treatment albumin values (<35 g/L or ≥35 g/L),  patients from 
the higher albumin group showed significant increase in prealbumin (p=0.005), and improved 
MIS (p=0.03). Multivariate regression analysis showed that higher FTI after introduction of 
L-carnitine led to greater hemodynamic stability (OR 1.709, 95% CI 1.006-2.905, p=0.048). As 
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there was no differences in HD treatment characteristics, primery kidney disease or residual 
diuresis we could conclude that positive energy balance (with an increase in prealbumin and 
FTI) eventually led to better hemodynamic stability. Conclusion: Our results show significant 
effects of L-carnitine supplementation on lipid metabolism. Further clinical trials, as well as 
experimental research are needed to define the role of lipid metabolism in CKD population. 
Significant benefits of L-carnitine supplementation in patients with better initial serum albumin 
levels suggest that this therapy should not be restricted to patients with the worst nutritional 
and overall status.
IntroductionCarnitine is an essential enzyme co-factor in energy metabolism, playing a vital role in 
β-oxidation of long-chain fatty acids [1, 2]. Given the crucial role it plays, carnitine plasma 
and tissue concentrations should be maintained relatively constant. Through tubular 
reabsorption, L-carnitine synthesis and selective short-chain carnitine esters excretion 
kidney is one of the key elements in preserving this balance [3]. Thus, chronic kidney disease 
(CKD) leads to significant disturbances of carnitine homeostasis, especially free plasma 
carnitine levels and carnitine muscle deposits [4]. Dialysis-related carnitine deficiency 
(defined as predialysis plasma concentration of free carnitine < 40 μmol/L) presents as 
the overlapping of anemia hyporesponsive to erythropoietin (EPO) therapy, intradialytic 
hypotension (IDH), cardiovascular (CV) complications and skeletal muscle dysfunction [5]. 
However, results of L-carnitine supplementation in hemodialysis (HD) patients have been 
conflicting. Some reports claimed L-carnitine to have a benefitial effect on mitigating EPO 
hyporesponsiveness, reducing dialysis-related muscle cramping and meliorating serum lipid 
profile [6-8]. Other studies failed to demonstrate such effects [9, 10].
With its major role as a metabolic intermediate, we hypothesized that L-carnitine 
supplementation could improve nutritional status in HD patients. The main aim of this 
prospective study was to evaluate the effectiveness of intravenous L-carnitine in mitigating 
dialysis-related protein-energy wasting (PEW) based on pretreatment albumin levels.
Materials and Methods
The current study was performed at the dialysis unit in the University hospital centre (UHC) Zagreb. 
Study was approved by the UHC Zagreb Ethics commitee. Among 121 patients treated at our unit, a total of 50 
patients received 1 g L-carnitine (Carnitene Sigma-Tau, Alfasigma Group) intravenously (5 ml of preparation 
applied slowly within 2-3 minutes) at the end of every HD session for 12 months. Inclusion criteria were as 
follows: at least 6 months of HD treatment, poor appetite with unintentional weight loss ≥ 5% over 3 months, 
and signs of PEW with serum albumin levels ≤ 38 g/L and Malnutrition-Inflammation Score (MIS) ≥ 5. 
Exclusion criteria were uncontrolled and untreated malignant disease, diabetes mellitus and lipid lowering 
therapy. Clinical data were obtained from the medical records and charts. This included demographic data, 
underlying kidney disease, HD vintage and treatment characteristics (duration, ultrafiltration (UF) rate, 
blood flow,  Kt/V), EPO therapy and intravenous iron dose, blood pressure (BP) before and after dialysis 
session as well as residual kidney function (daily urine output > 300 ml). IDH periods (defined as a decrease 
of systolic blood pressure by ≥ 20 mmHg) were recorded. The following dietary habits were evaluated using 
a self-administered questionnaire prior to L-carnitine supplementation – number of meals per day, skipping 
breakfast, skipping intradialytic meal and number of meat products consumated weekly. Appetite was 
graded 6 and 12 months after the start of supplementation. Laboratory parameters were measured prior to 
the supplementation and controlled in 6-months intervals. Anthropometric measurements were performed 
prior to HD session, including „dry“ body weight and height, body mass index (BMI), and body composition 
analysis using bioimpedance spectroscopy (The Fresenius Medical Care Body Composition Monitor – BCM). 
MIS was used as a scoring system representing the severity of PEW and an indicator of general functional 
capacity [11].
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Statistical analysis
Statistical analysis was performed using Stata/SE 11.2 for Windows (StataCorp LP, USA). Differences 
between two groups were analyzed by Pearson’s c2 test, (or Fisher’s exact test if any expected cell frequency 
in contingency table was ≤ 5) for categorical variables, by Student’s t-test for normally distributed continuous 
variables and by Wilcoxon test for non-normally distributed continuous variables, at the level of significance 
P < 0.05. Spearman Rank Order Correlations was used to determine correlation between variables.
Results
There were 23 male (46%) and 27 female (54%) patients, mean age 63±18.28 
years. The leading cause of CKD was chronic glomerulonephritis (36%), followed by 
nephroangiosclerosis (18%) and polycystic kidney disease (PKD) (16%). The median time 
spent on HD was 37.5 (7-288) months, with a minimum treatment time of 3 hours for 2 to 4 
times a week, blood flow rate 290.8 (250-350) ml/min and average Kt/V 1.29. Bicarbonate 
HD and ultrapure dialysate with a flow rate of 500 ml/min was used for all patients, as well 
as high-flux polysulphone dialysers. Symptomatic IDH occurred in 26% of patients (in 9.79% 
of dialysis sessons) prior to L-carnitine applications. The primary kidney disease had no 
influence on neither nutritional parameters nor on L-carnitine supplementation effects. 
Wilcoxon test revealed that L-carnitine supplementation in our cohort did not influence 
hemoglobin levels nor led to erythropoetin or intravenous iron dose modifications. There 
were 8 patients with PKD. Their hemoglobin value was 118 g/L (range 99.8-128.5) before, 
and 116.5 g/L (range 95.8-137) (p=0.73) after the treatment with L-carnitine, while patients 
with other primary kidney diseases had hemoglobin levels 109 g/L (range 96-115) before, 
and 110 g/L (104.5-118) after the treatment with L-carnitine, respectively (p=0.51).
L-carnitine supplementation had pronounced effects on lipid metabolism during the 
one-year period. Serum concentrations of HDL cholesterol decreased, while LDL cholesterol 
levels and fat tissue index (FTI) significantly increased. Although prealbumin fraction 
increased lean tissue index (LTI) fell, thereby leading to decreased LTI/FTI ratio (Table 1).
Table 1. Parameters in both groups according to albumin values prior and after L-carnitine supplementation. 
*Wilcoxon test 
Parameter Serum albumin < 35 g/L median (interquartile range) P* Serum albumin ≥ 35 g/L median (interquartile range) P* Prior (N=12) After (N=11) Prior (N=37) After (N=33) Body weight (kg) 70.5 (59 - 81.83) 74 (55 - 89) 0.201 67 (44 - 112) 67 (44 - 112) 0.456 Body height (cm) 171 (159 - 181) 168 (164 - 181) 0.500 167 (153 - 160) 168 (153 - 179) 0.366 BMI (kg/m2) 24.5 (20.68 - 30) 26.1 (21.86 - 33.09) 0.513 24.35 (17.1 - 35) 24.84 (16.85-33.81) 0.931 Cholesterol (mmol/L) 3.65 (3.15 - 4.68) 3.4 (2.8 - 5.1) 0.648 4 (2.2 - 7.8) 4.1 (2.6 - 8.4) 0.049 Triglycerides (mmol/L) 0.89 (0.08 - 5.13) 1.12 (0.1 - 3.05) 0.112 1.25 (0.52 - 35.13) 1.47 (0.29 - 26.14) 0.226 HDL (mmol/L) 1.17 (0.22 - 1.88) 1.08 (0.67 - 2.08) 0.495 1.07 (0.68 - 2.13) 0.92 (0.6 - 1.9) 0.002 LDL (mmol/L) 1.79 (0.89 - 3.65) 1.87 (0.44 - 3.56) 0.280 2.32 (0.81 - 5.14) 2.54 (1.65 - 5.38) 0.007 Hemoglobin (g/L) 109 (92.5-118.25) 113 (104-119) 0.158 111 (85-150) 108 (91-147) 0.627 
Ferritin (μg/L) 190.25 (19.9-833.1) 210.6 (67.7-1025) 0.009 359 (37.5-1141) 412.1 (35.2-1034) 0.133 
Iron (μmol/L) 14.5 (7-25) 10 (3-18) 0.139 11 (5-33) 14 (5-27) 0.329 EPO dose (IU/month) 32000 (8000-48000) 48000 (16000-48000) 0.99 32000 (0-72000) 24000 (0-64000) 0.596 IV Fe dose (mg/month) 125 (0-250) 125 (0-250) 0.102 125 (0-400) 122 (0-250) 0.027 Potassium (mmol/L) 4.3 (3.5 - 5.7) 4.9 (3.8 - 6.2) 0.055 5.1 (4.3 - 7.2) 5.3 (3.8 - 6.4) 0.637 Calcium (mmol/L) 2.33 (2.17 - 2.52) 2.28 (2.02 - 2.48) 0.198 2.24 (1.95 - 2.71) 2.26 (1.9 - 2.7) 0.467 Phosphorus (mmol/L) 1.41 (0.72 - 2.13) 1.33 (0.36 - 2.25) 0.363 1.68 (0.74 - 3.07) 1.82 (0.87 - 3.32) 0.047 Total protein (g/L) 63 (51 - 69) 60 (45 - 75) 0.875 66 (56 - 77) 67 (60 - 75) 0.105 Serum albumin (g/L) 34.25 (31 - 35) 33.2 (26.1 - 34.8) 0.280 37.6 (35.2 - 44.2) 38.7 (35.3 - 44.3) 0.338 MIS 11.5 (6 - 16) 11 (8 - 18) 0.899 8 (5 - 13) 6 (2 - 15) 0.030 Prealbumin (g/L) 0.45 (0.3 - 0.7) 0.5 (0.4 - 1.7) 0.055 0.6 (0.4 - 0.8) 0.7 (0.4 - 0.9) 0.005 Overhydration (L) 2.05 (-0.7 - 6.8) 2.1 (0.1 - 5.1) 0.753 2.2 (-2.1 - 6.8) 2.1 (-9 - 5.2) 0.532 LTI (kg/m2) 11.1 (6.6 - 15.6) 9.5 (5.8 - 14.4) 0.140 12.9 (8.8 - 21.1) 11.25 (6.4 - 15.3) 0.004 FTI (kg/m2) 12.15 (0.5 - 24) 16.3 (2.7 - 26.2) 0.293 10.65 (4.7 - 23.3) 13 (4.1 - 21.4) 0.001 LTI/FTI ratio 0.93 (0.29 - 28.6) 0.55 (0.22 -  4.52) 0.088 1.27 (0.38 - 3.26) 0.98 (0.34 - 3.32) 0.005  
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When divided into two groups 
according to the pre-treatment albumin 
values (<35 g/L or ≥35 g/L), patients 
in the low albumin group increased 
prealbumin from 0.45 to 0.5 g/L 
(p=0.055) and slightly decreased MIS 
from 11.5 to 11 (p=0.899) (Fig. 1, A and 
B). However, patients from the higher 
albumin group showed significant 
increase in prealbumin from 0.6 to 0.7 g/L 
(p=0.005), and improved MIS from 8 to 6 
(p=0.03, Fig. 2, A and B). These patients 
also showed significant improvement in 
appetite and better functional capacity 
(Fisher’s exact test, p=0.021). The same 
effects of L-carnitine supplementation 
were also clearly present after analyzing 
the patients according to their primary 
kidney disease (PKD vs. other primary 
kidney disease, Table 2). Groups did not 
differ regarding the number of dialysis 
sessions per week (average 2.92 vs. 2.89, 
p=0.56), dialysis vintage (median 103.5 
(12-110) vs. 98 (7-288) months, p=0.64), 
Kt/V (mean 1.2±0.33 vs. 1.31±0.22, 
p=0.62) or residual diuresis (median 750 
(0-2000) vs 560 (0-2000) ml, p=0.35) for 
the albumin <35 g/L or ≥35 g/L group, 
respectively. There was also no differences 
in dietary habits among the groups.
Before the introduction of L-carnitine, 
with the increase of BMI, FTI also 
increased (Rho=0.758, p<0.001), with a 
reduction of LTI/FTI ratio (Spearman Rho 
=-0.571, p<0.001, Fig. 3, A and B). After 
the introduction of L-carnitine, these 
correlations were more pronounced (Rho 
0.770 and -0.582, respectively, p<0.001). 
Multivariate regression analysis showed 
that higher FTI after introduction of 
L-carnitine led to greater hemodynamic 
stability with number of IDH episodes 
significantly decreasing during the 
12-months period (OR 1.709, 95% CI 1.006-2.905, p=0.048), and appearing in only 8% of 
patients (in 5.48% of dialysis sessions; Fisher’s exact test, p=0.049, Table 3).
L-carnitine treatment had no negative repercussions on dialysis adequacy (average Kt/V 
was 1.29 before and 1.32 after the treatment with L-carnitine, Fisher’s exact test p=0.24), 
nor were there any adverse events of the treatment.
Fig. 1. Changes in Malnutrition-Inflammation Score 
after L-carnitine supplementation according to 
pretreatment albumin values.
Figure 1. 
A     B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 2. Changes in prealbumin after L-carnitine 
supplementation according to pretreatment albumin 
values.
Figure 2.  
A     B 
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Discussion
Our results demonstrated marked effects of intravenous L-carnitine supplementation 
on lipid metabolism. A significant increase in total cholesterol, predominantly on the 
account of LDL was found. Simultaneously, HDL decreased while triglyceride levels remained 
unchanged. Although the rise in serum prealbumin could be observed, LTI decreased and FTI 
increased which resulted in reduction of the LTI/FTI ratio. Alhough at first these changes 
appear as negative, they were associated with improved hemodynamic stability, MIS and 
appetite, and were more pronounced in patients with better initial albumin levels.
Table 3. Distibution of patients with and without hypotension prior and after L-carnitine supplementation. 
* Fisher’s exact test
 
Parameter Number (%) of patients prior to L-carnitine supplementation P* Without hypotension With hypotension Total After L-carnitine supplementation Without hypotension 36 (97) 10 (77) 46 (92) 0.049 With hypotension 1 (3) 3 (23) 4 (8)  Total 37 (100) 13 (100) 50 (100)  
 
Table 2. Parameters in groups according to primary kidney disease prior and after L-carnitine 
supplementation. *Wilcoxon test
Parameter Polycystic kidney disease (n=8) median (interquartile range) P* Other primary diseases (n=42) median (interquartile range) P* Prior After Prior After Body weight (kg) 59.2 (53 – 69.6) 62.5 (54.1 – 67.3) 0.6 69.7 (57 – 81.5) 70 (54.5 - 84) 0.46 Body height (cm) 160 (160 - 170) 170 (160 – 159.8) 0.14 170 (160 - 180) 170 (160 - 170) 0.12 BMI (kg/m2) 22.8 (21.3 – 26.3) 26.1 (21.86 - 33.09) 0.513 24.8 (17.1 - 35) 24.9 (20.6-28.8) 0.35 Cholesterol (mmol/L) 4.2 (3.6 – 5.3) 4.7 (3.6 - 5.4) 0.36 3.9 (3.25 – 4.7) 4.1 (3.4 – 5.1) 0.17 Triglycerides (mmol/L) 1.1 (0.9 - 1.5) 1.7 (1.2 - 2.2) 0.02 1.25 (0.52 - 35.13) 1.47 (0.29 - 26.14) 0.04 HDL (mmol/L) 1.3 (1.1 - 1.3) 1.1 (0.8 – 1.2) 0.02 1.1 (0.9 – 1.3) 1.0 (0.8 - 1.3) 0.02 LDL (mmol/L) 2.5 (1.8 - 3.3) 2.7 (2 – 3.4) 0.4 2.0 (1.6 – 2.9) 2.3 (1.9 – 3.1) 0.008 Hemoglobin (g/L) 118 (99.8 – 128.5) 116.5 (95.8-137) 0.73 109 (96-115) 110 (104.5 - 118) 0.51 
Iron (μmol/L) 9.5 (8 – 11.8) 14 (10.5 – 17.3) 0.5 11 (8 - 16) 11 (8.5 - 16) 0.37 EPO dose (IU/month) 20000 (6000-24000) 24000 (0-36000) 0.66 32000 (0-72000) 24000 (0-64000) 0.596 IV Fe dose (mg/month) 187.5 (32.8 - 250) 125 (0 - 250) 0.18 125 (93.8-250) 125 (31.3-162.5) 0.14 Total protein (g/L) 66 (63.3 – 72.3) 67.5 (64.3 – 73.5) >0.99 65 (62 - 68) 66 (62 – 68.75) 0.18 Serum albumin (g/L) 37.1 (36.1 – 39.9) 37.1 (35.4 – 41.2) 0.46 37 (34.9 - 39) 37.6 (34.5 - 40.2) 0.94 MIS 7.5 (6 – 8.8) 6 (5 – 9.5) 0.010 9 (6.8 - 11) 8 (6 – 10.3) 0.049 Prealbumin (g/L) 0.6 (0.6 - 0.7) 0.7 (0.5 – 0.8) 0.02 0.6 (0.5 - 0.7) 0.7 (0.5 - 0.7) 0.003 Overhydration (L) 1.8 (0.1 - 4.8) 1.6 (0 - 3.1) 0.14 2 (0.9 – 3.7) 2.3 (0.9 - 4) 0.67 LTI (kg/m2) 11.6 (10.6 - 14) 9.4 (7.2 - 11.9) 0.01 12.5 (10.1 – 13.9) 11.2 (9.9 – 12.9) 0.04 FTI (kg/m2) 10.4 (8 – 13.1) 14.8 (10 - 18) 0.02 10.8 (7.7 – 15.2) 13 (8.1 – 16.9) 0.03 LTI/FTI ratio 1.3 (0.9 – 1.5) 0.8 (0.4 -  1) 0.01 1.2 (0.8 – 1.8) 0.9 (0.6 – 1.5) 0.02  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Changes in LTI/FTI ratio after L-carnitine 
supplementation according to pretreatment 
albumin values.
Figure 3.  
A     B 
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Our study showed that 12 months of intravenous L-carnitine supplementation had 
no impact on hemoglobin levels nor did it lead to a reduction in EPO requirement. This 
finding is in accordance with Handelman’s study from 2006 which showed that 6 months 
of L-carnitine administration to patients in a large dialysis unit did not change hemoglobin 
or EPO dose [12]. Meta-analysis by Hurot et al. suggested a beneficial effect of L-carnitine 
supplement on anaemia control in HD patients with reducing the EPO resistance index and 
improving EPO efficiency as compared with control groups. They were not able to find dose-
response pattern, and did not observe a time gap for this effect [13]. Due to small number of 
studies and limited number of patients Chen et al. recently conducted another meta-analysis 
which failed to confirm those findings [8].
According to our results, L-carnitine supplementation significantly decreased number of 
IDH episodes (OR 1.709, 95% CI 1.006-2.905, p=0.048), complicating only 5.48% of dialysis 
sessions; Fisher’s exact test, p=0.049). IDH is a common complication of HD which could 
lead to premature treatment discontinuation, chronic underdialysis and higher mortality. 
It is mainly linked to poor compensatory response to ultrafiltration, with autonomic or 
baroreceptor failure or disturbed cardiac function leading to excessive venous pooling and 
abnormal vasodilation [14]. New evidence also suggests that mitochondria dysfunction 
might have a primary role in the development of CKD related complications. This results in 
mitochondria-derived oxidative stress and leads to persistent tissue damage. As L-carnitine 
is an essential enzyme co-factor in energy metabolism it could be one of the so called 
mitochondria-targeted molecules which could modulate the specific signal transduction 
cascade and lead to significant improvement of cellular defense against chronic inflammation 
and oxidative stress [15]. Moreover, after performing multivariate regression analysis we 
were able to show a link between the FTI increase and a lesser number of IDH episodes 
which could suggest that positive energy balance (with an increase in prealbumin and FTI) 
and a reduction of MIS eventually led to better hemodynamic stability.
The relationship between L-carnitine therapy and lipid metabolism has been widely 
investigated but with conflicting results. Our data are in contrast with previously published 
studies which described either beneficial effects or no changes at all. By beneficial effects 
authors have stressed a significant decline in triglycerides, free fatty acids and cholesterol 
levels (total and LDL fraction) and an increase in HDL [16-19]. On the other hand, results 
obtained by two systematic reviews and meta-analysis provided no evidence that L-carnitine 
could impact lipid metabolism [13, 20]. These differences could possibly be explained by the 
dose-dependent effects of carnitine proposed by some reports [8, 21].
Cardiovascular (CV) complications are the leading cause of mortality in HD patients, with 
accelerated atherosclerosis and PEW being among the most important risk factors leading to 
poor outcome [22]. Although obesity, hypercholesterolemia and higher BP values are well-
established risk factors for CV disease and poor outcome in general population, it seems 
that higher rather than lower values for these risk factors act protective in CKD patients [23-
26]. This phenomenon is called „reverse epidemiology“ or „dialysis-risk-paradox“ [23, 26, 
27]. Several possible mechanisms explaining favorable effect of higher BMI on survival have 
been proposed so far. All hypothetical explantations lead to one particular point – adipose 
tissue does not serve only as lipid storage but is also a highly active endocrine organ [28, 
29]. As PEW is defined not only by the continuous decline in protein but also fat reserves, its 
treatment represents a challenge and should be focused on maintaining the energy pool as 
whole.
Even though our results are contradictory to previously published studies [13, 16-20], 
one could speculate whether this slight but significant increase in total and LDL cholesterol 
and FTI could in fact be protective in HD patients. Although at first these changes could 
be claimed as undesirable they led to significant amelioration of MIS and were linked to 
much better appetite. Furthermore, FTI increase led to lesser number of IDH episodes.  As 
there was no differences in HD treatment characteristics, primery kidney disease or residual 
diuresis we could conclude that positive energy balance (with an increase in prealbumin 
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and FTI) eventually led to better hemodynamic stability. This hypothesis deserves further 
investigations. Although L-carnitine treatment had no negative repercussions on Kt/V 
indeces, dialysis adequacy parameters should be carefully monitored.
Our study has some limitations including the small sample size, lack of control group, 
limited laboratory lipid-metabolism evaluation and short follow-up. When evaluating dietary 
habits by using a self-administered questionnaire prior to L-carnitine supplementation there 
was no differences between these two groups. However, more detailed food intake analysis 
was not performed. Thus, there is a possibility that the former group did not have the same 
dietary habits as the other analyzed group. Although this may be the potential source of a 
bias, patients from the higher albumin group clearly stated improvements in appetite and 
functional capacity that in our oppinion led to better serum prealbumin and a decrease in 
MIS. This was also mirrored through the changes in serum lipid profile and phosporus levels.
Additionally, comparing both pre- and postdialysis body composition measurements as 
well as more detailed food intake analysis might be useful in further studies. Further clinical 
trials, as well as experimental research are needed to define the role of lipid metabolism in 
CKD population.
Conclusion
The results of our study showed significant effects of L-carnitine supplementation on 
lipid metabolism. Significance of increase in the FTI remains unclear, although it may be the 
consequence of increase in the“healthy“ and protective fat tissue. Due to significant benefits 
of L-carnitine supplementation in patients with better initial serum albumin levels, this 
therapy should not be restricted to patients with the worst nutritional and overall status.
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